MyStoria Raises $1.625M Seed Round Led by Graphite Ventures

Why It Matters

By giving patients a coordinated, AI‑enhanced navigation tool, myStoria reduces diagnostic delays and fragmented care, unlocking a scalable infrastructure that could reshape chronic‑disease management across the health system.

Key Takeaways

• Seed round raises $1.19 M USD for AI health platform.
• Platform covers PCOS, endometriosis, perimenopause, fertility.
• Human‑in‑the‑loop AI ensures personalized patient guidance.
• Aims to become reusable infrastructure beyond reproductive health.
• Freemium app launches on iOS and Android.

Pulse Analysis

The reproductive‑health market has long suffered from prolonged diagnostic timelines and siloed specialist care, leaving patients to juggle appointments, test results, and insurance paperwork. myStoria’s entry arrives at a moment when digital‑health solutions are seeking to address these inefficiencies, especially for conditions like PCOS and endometriosis that often go undiagnosed for years. By aggregating all patient‑generated data—documents, audio notes, photos—into a structured “Context Engine,” the platform creates a single source of truth that both AI algorithms and human clinicians can reference, dramatically reducing the administrative burden on patients.

myStoria’s hybrid model leverages artificial intelligence for rapid information synthesis while retaining clinicians in the loop to validate and contextualize recommendations. This approach not only improves accuracy but also builds a defensible data moat, as highlighted by Graphite Ventures’ investment thesis. The $1.625 million seed round, positioned at the top of Graphite’s typical $500 K‑$1.5 M range, signals strong investor confidence in patient‑owned health infrastructure. The freemium launch on iOS and Android lowers entry barriers, allowing the company to scale user acquisition while gathering longitudinal data essential for refining its AI.

Looking ahead, myStoria’s vision extends beyond reproductive health, aiming to replicate its infrastructure for chronic conditions such as cancer, cardiovascular disease, and autoimmune disorders. If successful, the platform could become a universal care‑coordination layer, attracting partnerships with insurers and health systems seeking to improve outcomes while curbing costs. The convergence of AI, data ownership, and venture capital backing positions myStoria as a potential catalyst for a broader shift toward patient‑centric, technology‑enabled healthcare ecosystems.

Deal Summary

Ontario startup myStoria announced a $1.625 million seed round to expand its AI‑driven reproductive health platform. The round was led by Graphite Ventures with participation from Conexus Venture Capital, Adrenaline Fund, Phoenix Fire Fund and strategic angel investors. The funding will support product expansion across PCOS, endometriosis, perimenopause and other reproductive health conditions.